INVESTOR RELATIONS

Track all markets on TradingView

SCINAI IMMUNOTHERAPEUTICS
(NASDAQ: SCNI)
COMPANY OVERVIEW

Scinai is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bio-services business unit.

With over 20 years of experience in recombinant protein process development and cGMP manufacturing, Scinai is on a mission to elevate drug development. Every step of the way.

Our Business Units

Scinai operates with two complementing Business Units: R&D and CDMO Bioservices.

Featured
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai Regains Full Compliance with Nasdaq Listing Requirements
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000  
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Latest News

EVENTS

Featured
EADV
Sep. 25

Sign up for news and updates

Sign up with your email address.

Q2 2024

LATEST FINANCIAL RESULTS

SEC

Analyst & Investor Webinar

ANNUAL REPORTS 2023

QUARTERLY REPORTS

  • Q1 2023

  • PRESS RELEASE

  • SEC FILINGS

Governance

Contact us